Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

MLA

Subbiah, Vivek, et al. “Dabrafenib plus Trametinib in Patients with BRAFV600E-Mutated Biliary Tract Cancer (ROAR): A Phase 2, Open-Label, Single-Arm, Multicentre Basket Trial.” Lancet Oncology, vol. 21, no. 9, Sept. 2020, pp. 1234–43. EBSCOhost, https://doi.org/10.1016/S1470-2045(20)30321-1.

APA

Subbiah, V., Lassen, U., Élez, E., Italiano, A., Curigliano, G., Javle, M., de Braud, F., Prager, G. W., Greil, R., Stein, A., Fasolo, A., Schellens, J. H. M., Wen, P. Y., Viele, K., Boran, A. D., Gasal, E., Burgess, P., Ilankumaran, P., & Wainberg, Z. A. (2020). Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncology, 21(9), 1234–1243. https://doi.org/10.1016/S1470-2045(20)30321-1

Chicago

Subbiah, Vivek, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, et al. 2020. “Dabrafenib plus Trametinib in Patients with BRAFV600E-Mutated Biliary Tract Cancer (ROAR): A Phase 2, Open-Label, Single-Arm, Multicentre Basket Trial.” Lancet Oncology 21 (9): 1234–43. doi:10.1016/S1470-2045(20)30321-1.